Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41598-020-66440-9 http://scihub22266oqcxt.onion/10.1038/s41598-020-66440-9 32518317!7283245!32518317     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Sci+Rep 2020 ; 10 (1): 9294 Nephropedia Template TP {{tp|p=32518317|t=2020. Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic |pdf=|usr=}}{{32518317}} gab.com Text Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic JO: Sci Rep http://www.kidney.de/pget.php?&tw=1&pmid=32518317 #FOAvip As of today, there is no antiviral for the treatment of the SARS-CoV-2 infection, and the development of a vaccine might take several months or even years. The structural superposition of the hepatitis C virus polymerase bound to sofosbuvir, a nucleoside analog antiviral approved for hepatitis C virus infections, with the SARS-CoV polymerase shows that the residues that bind to the drug are present in the latter. Moreover, a multiple alignment of several SARS-CoV-2, SARS and MERS-related coronaviruses polymerases shows that these residues are conserved in all these viruses, opening the possibility to use sofosbuvir against these highly infectious pathogens. Twit Text FOAVip Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic ????Sci Rep http://www.kidney.de/pget.php?&tw=1&pmid=32518317 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32518317 #FOAvip English Wikipedia <ref>{{Cite pmid|32518317}}</ref> Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic #MMPMID32518317 Jacome R; Campillo-Balderas JA; Ponce de Leon S; Becerra A; Lazcano A Sci Rep 2020[Jun]; 10 (1): 9294 PMID32518317show ga As of today, there is no antiviral for the treatment of the SARS-CoV-2 infection, and the development of a vaccine might take several months or even years. The structural superposition of the hepatitis C virus polymerase bound to sofosbuvir, a nucleoside analog antiviral approved for hepatitis C virus infections, with the SARS-CoV polymerase shows that the residues that bind to the drug are present in the latter. Moreover, a multiple alignment of several SARS-CoV-2, SARS and MERS-related coronaviruses polymerases shows that these residues are conserved in all these viruses, opening the possibility to use sofosbuvir against these highly infectious pathogens. |Antiviral Agents/*chemistry/therapeutic use[MESH] |Base Sequence[MESH] |Betacoronavirus/*enzymology[MESH] |COVID-19[MESH] |Catalytic Domain[MESH] |Computer Simulation[MESH] |Coronavirus Infections/drug therapy/*virology[MESH] |Coronavirus RNA-Dependent RNA Polymerase[MESH] |Humans[MESH] |Middle East Respiratory Syndrome Coronavirus/enzymology[MESH] |Pandemics/*prevention & control[MESH] |Pneumonia, Viral/drug therapy/*virology[MESH] |Protein Binding[MESH] |Protein Structure, Tertiary[MESH] |RNA-Dependent RNA Polymerase/*chemistry/genetics[MESH] |SARS-CoV-2[MESH] |Severe Acute Respiratory Syndrome/drug therapy/virology[MESH] |Severe acute respiratory syndrome-related coronavirus/enzymology[MESH] |Sofosbuvir/*chemistry/therapeutic use[MESH]Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic(epmc).pdf DeepDyve Pubget Overpricing